The supplement industry generates an estimated $50 billion a year in the United States. Most of that money is spent by people who genuinely believe what they read on the label. The problem is what they read on the label is, in many cases, designed to be technically legal while still misleading them about what the product can actually do.

This post is the long version of something I have written about in pieces across this site, mostly in brand reviews where individual companies have been caught making claims that did not hold up. The point of this post is to step back from any single brand and look at the system itself. The legal structure of supplement labeling in the United States allows companies to say things on a bottle that imply medical benefits without ever having to prove those benefits work. People who are sick, exhausted, struggling with their weight, or watching a parent decline from dementia are the primary audience for this kind of marketing. They are also the people least equipped to read past it.

I am not a regulator. I am not a lawyer. I am someone who got into this category because I have celiac disease and I take mushroom supplements personally, and along the way I learned how this industry actually operates. Once you understand the rules, the marketing patterns become impossible to unsee. That is what this post is about.

The law that made all of this possible

In 1994, Congress passed the Dietary Supplement Health and Education Act, known as DSHEA. Before DSHEA, dietary supplements were regulated more like food additives, and any health claim had to be approved by the FDA before it appeared on a label. After DSHEA, supplements got their own regulatory category, and a new set of rules took effect that completely changed what companies could say on their packaging.

The core change was this. Supplement companies were given the ability to make what are called structure and function claims without prior FDA approval. The FDA does not review these claims before the product hits the shelf. The company is required to have what the law calls “competent and reliable scientific evidence” to support the claim, but they do not have to submit that evidence to the FDA, and the FDA only has voluntary standards for what counts as adequate evidence [1][2].

That is the loophole the entire industry was built around. The FDA cannot stop a supplement claim from going to market. They can only act after the fact, if they happen to investigate the company and find that the claims were unsubstantiated or that the product was making prohibited disease claims. Given the size of the industry and the resources the FDA actually has, this happens to a very small fraction of products.

A 2012 Office of Inspector General study published by the Department of Health and Human Services analyzed 127 dietary supplements marketed for weight loss or immune support. The findings were not subtle. Substantiation documents that companies provided when asked were “inconsistent with FDA guidance on competent and reliable scientific evidence.” Twenty percent of the supplements included prohibited disease claims on their labels. Seven percent lacked the required FDA disclaimer entirely [1].

That study is now over a decade old. The industry has grown substantially since then. The FDA’s resources have not kept pace.

What a structure and function claim actually is, and why it matters

A structure and function claim describes how a nutrient or ingredient affects the structure or function of the human body without claiming to treat a disease. The classic textbook examples are statements like “calcium builds strong bones” or “fiber maintains bowel regularity” [3]. These are technically permissible because they describe biological function rather than disease prevention.

The problem is what happens at the edges of that definition. A label that says “supports a healthy immune system” is a structure and function claim. A label that says “prevents colds” is a disease claim and is illegal without FDA approval. The first one is allowed. The second one is not. To consumers, they sound like they describe roughly the same thing.

This is not an accident. Manufacturers strategically phrase claims to sit on the legal side of that line while implying the medical benefit on the consumer side of it. The Congressional Research Service noted in 2025 that “a manufacturer may make a strategic choice to phrase a claim so that it is a structure/function claim and not a health claim to avoid the premarket approval requirement and the more rigorous standard associated with health claims” [4]. That is the federal government acknowledging, in a research report, that this is how the system actually works.

The same product can carry phrases like “supports cognitive function” and “promotes mental clarity” without any premarket review of whether the product actually does either of those things. The company is supposed to have evidence somewhere. They are not required to show it to anyone unless they get caught.

The disclaimer that is supposed to protect you

If you look at any supplement bottle, somewhere on the label, usually in small text on the back, you will find a sentence that reads something close to this:

“These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

That is the FDA-required disclaimer that has to accompany any structure and function claim [5]. It exists because the law requires the company to tell you, in writing, that the claims on the front of the bottle were not reviewed or approved by anyone.

Almost no consumer reads it. The disclaimer is in 6 to 8 point type, on the back of the bottle, often in gray rather than black, while the claims are in 18 to 24 point bold type on the front. The legal protection is technically there. The practical protection is not.

This is the gap that drives most of the deceptive marketing in the category. Companies put bold, confident, benefit-forward language on the front of the bottle, and they put the disclaimer on the back where almost no one will read it. The structure of the law requires them to disclose. The structure of the design ensures that disclosure does nothing.

I am not arguing the disclaimer should be on the front of every bottle. I am arguing that, as currently implemented, it does not function as the consumer protection mechanism it was intended to be. People do not read fine print. They read the headline. The headline is the marketing claim. The marketing claim was never reviewed.

The actual deceptive practices, ranked by harm

Not every supplement company is doing the same thing. There is a real spectrum from honest brands that publish their certificates of analysis and stay carefully on the legal side of claim structure, all the way to outright fraud operations using fake celebrity endorsements. The middle of that spectrum is where most of the harm happens, because it is also where most of the volume happens.

Tier 1: Implied disease claims that legally qualify as structure and function claims. This is where most legal-but-misleading supplement marketing lives. A weight loss supplement that says “supports healthy metabolism” is implying weight loss without legally claiming it. A cognitive supplement that says “supports memory function” is implying it treats dementia or age-related cognitive decline without legally claiming that. The buyer fills in the meaning. The company never had to substantiate it.

Tier 2: Selective citation of preliminary research. A company finds a single in-vitro or animal study showing some effect of an ingredient, then markets the product as if that effect has been demonstrated in humans at the dose the product delivers. The citation looks impressive. The actual relevance to whether the product does anything in your body is often zero. This is widespread in the cognitive enhancement, immune support, and adaptogen categories.

Tier 3: Influencer-driven testimonial marketing without disclosure. Influencer marketing is supposed to follow FTC endorsement guidelines that require disclosure of paid relationships. Many influencer posts in the supplement space comply technically with #ad disclosures, but the testimonial itself (“I have so much more energy since I started taking this”) implies clinical benefit without any clinical evidence. The disclosure protects the influencer. It does not protect the consumer from a claim that is unsubstantiated.

Tier 4: GLP-1 and prescription drug imitator marketing. This is the category that prompted the National Advertising Division’s 2025 inquiry into RYZE Superfoods. Supplements marketed with imagery, language, or visual styling that imply they deliver effects similar to prescription medications, without ever explicitly claiming so. The implied comparison reaches people who cannot afford or cannot access the actual prescription, and it offers them a non-prescription version that does not actually work the same way.

Tier 5: Fake reviews, fake celebrity endorsements, fake media sites. This is outright fraud territory. The 2018 FTC case against Tarr Inc. documented an “extensive network” of online marketers using fake media websites with domain names that appeared to be authentic news outlets including spoofed Men’s Health, Good Housekeeping, and Dr. Oz sites [6]. The April 2026 settlement with TruHeight involved a children’s height-enhancement supplement where the company allegedly paid for fake five-star reviews and used fake employee-written testimonials. The FTC settlement specifically called out reviews “that were not authentic” and the company offering “free products and discounts in exchange for posting five-star reviews” [7].

Recent enforcement: who got caught and what it took to catch them

The FTC has the authority to act against deceptive supplement advertising, but the agency has limited resources and a high evidence bar. When they do bring cases, the timelines are striking.

Prevagen. This is the memory supplement marketed heavily to older adults with claims about improving cognitive function. The FTC and the New York Attorney General first sued the makers of Prevagen, Quincy Bioscience, in 2017. After seven years of litigation including a jury trial, the U.S. District Court for the Southern District of New York ruled in December 2024 that the company had to cease making the deceptive claims [8]. Seven years. From a federal lawsuit to a court order. During that time, the product continued to sell, the marketing continued to run, and the audience the FTC was trying to protect (older Americans worried about memory loss) continued to be the primary purchasers.

Sobrenix. A supplement marketed as reducing alcohol cravings and helping with problematic drinking. The FTC announced in November 2024 that it would send refunds totaling more than $536,000 to 536,000 consumers who had been deceived by claims that the FTC ultimately determined had no scientific substantiation [9]. The deceptive practices included paid endorsements presented as independent expert opinions and review websites the company itself had drafted. Half a million consumers. One product. The refunds work out to roughly one dollar per affected buyer.

TruHeight. A height-enhancement supplement marketed to parents of children and teenagers with claims like “Help your child grow taller!” and “The Only Supplement Clinically Proven to Help Height Growth.” The April 2026 FTC settlement found the claims were “false or misleading, or were not substantiated.” Beyond the unsubstantiated claims, the FTC documented thousands of fake five-star reviews written by company employees and vendors, plus financial incentives offered to consumers in exchange for positive reviews [7]. The targets here were parents worried about their children’s growth.

Health Research Laboratories. Two Texas-based companies and their owner were banned from the supplement industry entirely in 2022 after the FTC documented unsubstantiated claims that supplements prevented or treated cardiovascular disease and diabetic neuropathy [10]. This was a banning order. They got banned, not fined. The original violations had been ongoing for years before the order took effect.

These are the cases that made it through to enforcement. The FTC’s own data suggests these represent a small fraction of the actual deceptive marketing in the industry. Cases take years. By the time a company is sanctioned, the product has often been generating revenue for half a decade or longer, and that money is gone.

The DNA testing problem: when the product does not even contain what it says it contains

Beyond marketing claims, there is a more fundamental issue with what is actually inside supplement bottles. Independent DNA testing studies have repeatedly found that significant percentages of herbal supplements do not contain the species listed on the label.

A 2024 Chapman University study published in Phytochemical Analysis tested 54 commercial Ayurvedic herbal supplements on the US market for nine targeted herb species. The expected species was detected in only 38.9 percent of products [11]. Undeclared plant species were detected in 19 of the 54 products. That is a roughly 60 percent failure rate for products to contain what their labels claimed they contained.